Investor Relations NEWS

2016.11.21 Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy

collaboration-and-commercialization-agreement-with-steminent-biotherapeutics

2015.11.24 Regarding the synergy effect of making Biopta Limited a wholly-owned subsidiary

Regarding the synergy effect of making Biopta Limited a wholly-owned subsidiary(1) Regarding the synergy effect of making Biopta Limited a wholly-owned subsidiary(2)  

2015.11.18 Notice concerning the publication of a paper concerning “3D culture model construction of mouse neurons” from a company in our group in the international neuroscience journal ‘Neuroscience Letters’

Notice concerning the publication of a paper concerning “3D culture model construction of mouse neurons” from a company in our group in the international neuroscience journal ‘Neuroscience Letters’

2015.11.16 PRODUCTA Joint Development with the National Cancer Cente: Information Regarding the Sale of “ReproHP Medium,” a Culture Fluid for Human Primary Liver Cells with High Levels of Functionality

A Joint Development with the National Cancer Cente: Information Regarding the Sale of “ReproHP Medium,” a Culture Fluid for Human Primary Liver Cells with High Levels of Functionality

2015.11.04 Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells

Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells

2015.10.19 The ReproCELL Group announces publication of a research report on “3D Skin Model Construction,” submitted to the International Scientific Journal “Molecular Cancer Therapeutics” by this corporate group and others.

20151019_The ReproCELL Group announces publication of a research report on “3D Skin Model Construction,” submitted to the International Scientific Journal “Molecular Cancer Therapeutics”

2015.10.14 The ReproCELL Group announces publication of a paper on its state-of-the-art RNA Reprogramming technology in Human Gene Therapy, an international journal.

The ReproCELL Group announces publication of a paper on its state-of-the-art RNA Reprogramming technology in Human Gene Therapy, an international journal.

2015.09.24 Joint Announcement with Ajinomoto Co., Inc.Notification of the Beginning of Sales of StemFIT® AK02N High-Performance Culture Solution for Regenerative Medicine Use Human iPS Cells

Joint Announcement with Ajinomoto Co., Inc.Notification of the Beginning of Sales of StemFIT® AK02N High-Performance Culture Solution for Regenerative Medicine Use Human iPS Cells

2015.09.08 Announcement: ReproCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells

ReproCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells

2015.08.26 Joint Press Announcement with Institute for Frontier Medical Sciences, Kyoto University: New high-performance cryopreservation solution for human ES/iPS cells used in regenerative medicine, Notice of the commencement of sales of “ReproCryo DMSO free”

Joint Press Announcement with Institute for Frontier Medical Sciences, Kyoto University: New high-performance cryopreservation solution for human ES/iPS cells used in regenerative medicine, Notice of the commencement of sales of “ReproCryo DMSO free”